Method for generation of broadly neutralizing anti-pathogen antibodies
AssigneeNortheastern University
InventorsMichail V. SITKOVSKY, Robert Koehler ABBOTT, Stephen Matthew HATFIELD
Life of this patent
Estimating the term…
Abstract
Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.
Claims26
A method for enhancing an immune response in a subject, comprising:
- administering, after vaccination of the subject, one or more immune enhancers selected from the group consisting of:
- (a) an A2a adenosine receptor agonist;
- (b) an A2b adenosine receptor agonist;
- (c) a hypoxia inducible factor;
- and
- (d) an agent that prevents the degradation of hypoxia inducible factors.
(canceled)
(canceled)
A method for enhancing an antibody titer in response to vaccination in a subject, comprising administering after vaccination of the subject, one or more immune enhancers selected from the group consisting of:
- (a) Gs protein coupled receptor antagonists;
- (b) Gi protein coupled receptor agonists;
- (c) an agent that inhibits the effects of tissue hypoxia;
- (d) an agent that inhibits the hypoxia inducible factor pathway;
- (e) an agent that inhibits the accumulation of extracellular adenosine;
- and
- (f) a treatment that inhibit the hypoxia inducible factor pathway.
-18. (canceled)
A method for stimulating B cells, ex vivo, to improve one or more of class switching, somatic mutation, and activation comprising:
- stimulating B cells in culture with antibodies, interleukins, and/or growth factors;
- and
- contacting the cells with a A2a receptor agonist and/or a A2b receptor agonist cell culture condition under hypoxic conditions.
-24. (canceled)
A method for potentiating a germinal center and/or cells within the germinal center in a subject, the method comprising:
- administering after vaccination of the subject, one or more immune enhancers selected from the group consisting of:
- (a) an A2a adenosine receptor agonist;
- (b) an A2b adenosine receptor agonist;
- (c) a hypoxia inducible factor;
- and
- (d) an agent that prevents the degradation of hypoxia inducible factors.
The method of claim 24, wherein the agent that potentiate or enhances the intracellular effects of A2a/A2b adenosine receptors or other Gs protein coupled receptors is one or more agents selected from the group consisting of:
- ibudilast, mesembrine, rolipram, piclamilast, luteolin, drotaverine, and roflumilast.
-34. (canceled)
Dependencies are inferred from the claim text.